MERCK & CO, INC. for MERCK & CO INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Oct 20, 2014 | $1,160,000 | Replaced |
| 3rd Quarter - Amendment | Jan 26, 2015 | $1,160,000 | Replaced |
| 3rd Quarter - Amendment | Oct 7, 2015 | $1,160,000 | Replaced |
| 3rd Quarter - Amendment (this page) | Sep 6, 2016 | $1,160,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FILIPPONE | — |
| ELI JOSEPH | — |
| KATIE OPPENHEIM | — |
| ERIN POLAK | — |
| ANGELA M STEWART | — |
Trade (domestic/foreign) TRD
Additives in beef cattle (no specific bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI JOSEPH | — |
| ERIN POLAK | — |
Copyright/Patent/Trademark CPT
Intellectual property (general education, no specific bill), patent reform (general education, no specific bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| ANGELA M STEWART | — |
Health Issues HCR
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| ROBERT FILIPPONE | — |
| ELI JOSEPH | — |
| PATRICK LIEDTKA | — |
| JEROME MURRAY | — |
| KATIE OPPENHEIM | — |
| ERIN POLAK | — |
| ANGELA M STEWART | — |
Medicare/Medicaid MMM
Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| ROBERT FILIPPONE | — |
| ELI JOSEPH | — |
| JEROME MURRAY | — |
| KATIE OPPENHEIM | — |
| ERIN POLAK | — |
| ANGELA M STEWART | — |
Animals ANI
Education on beta-agonists (no specific bill), education on antibiotics and veterinary biologics (no specific bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI JOSEPH | — |
| KATIE OPPENHEIM | — |
| ERIN POLAK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.